Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients
| Autor: | Nicole R. Zane, Kevin J. Downes, Brian T. Fisher |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Antifungal medicine.medical_specialty Antifungal Agents Drug-Related Side Effects and Adverse Reactions medicine.drug_class Article 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Pharmacokinetics Amphotericin B Humans Medicine Pharmacology (medical) Dosing Child Adverse effect Intensive care medicine 030203 arthritis & rheumatology medicine.diagnostic_test business.industry Infant Newborn Infant Therapeutic drug monitoring Child Preschool Pharmacodynamics Pediatrics Perinatology and Child Health Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Paediatr Drugs |
| ISSN: | 1179-2019 1174-5878 |
| Popis: | Neonates and immunosuppressed/immunocompromised pediatric patients are at high risk of invasive fungal diseases. Appropriate antifungal selection and optimized dosing are imperative to the successful prevention and treatment of these life-threatening infections. Conventional amphotericin b was the mainstay of antifungal therapy for many decades, but dose-limiting nephrotoxicity and infusion-related adverse events impeded its use. Despite the development of several new antifungal classes and agents in the past 20 years, and their now routine use in at-risk pediatric populations, there are limited data to guide optimal dosing of antifungals in children. This paper reviews the spectra of activity for approved antifungal agents and summarizes the current literature specific to pediatric patients regarding pharmacokinetic/pharmacodynamic data, dosing, and therapeutic drug monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink